Xencor, Inc.
Ticker
XNCR
ISIN
US98401F105
Price
USD 23.77
Change Today
+0.02 / 0.084 %
Price 1 year ago
26.51 / -10.336 %
Market Capitalization
1,628,712,576.00
52 Week Low
16.53
52 Week High
28.72
200 Day Moving Average
20.81
50-day Moving Average
21.65
Price evolution
Yearly Returns
Peers
Peers
Company information
Summary
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. Its product candidates include Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. In addition, it is developing VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. Further, the company is developing AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.
Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
NGM
Earnings Per Share
-1.212
P/E Ratio
-
Debt/Equity Ratio
4.573
Beta
0.613026
Ebitda
94,870,000.00
Ebitda Margins
0.29
Enterprise to Ebitda
14.27
Enterprise Value
1,353,425,792.00
Target Price
49.80
Estimated Price
-
Book Value
9.89
Expected Growth
-
Balance sheet
Income statement
Sustainability
Correlation
Company | Name | Correlation |
---|---|---|
2370.T | MEDINET CO LTD | -0.35 |
9939.HK | KINTOR PHARMA-B | -0.24 |
RIGL | Rigel Pharmaceuticals, Inc. | -0.11 |
DNA | Ginkgo Bioworks Holdings, Inc. | -0.10 |
IMU.AX | IMUGENE FPO | 0.01 |
1177.HK | SINO BIOPHARM | 0.15 |
NVAX | Novavax, Inc. | 0.17 |
BLUE | bluebird bio, Inc. | 0.18 |
2269.HK | WUXI BIO | 0.22 |
CLVS | Clovis Oncology, Inc. | 0.37 |
Similar companies
Ticker | Name | City | Country | Currency | Exchange | Beta | EV/EBITDA | Employees | Site |
---|---|---|---|---|---|---|---|---|---|
ALPHA.PA | PHARNEXT | Issy-les-Moulineaux | France | EUR | PAR | 2.86 | -0.65 | 40 | https://www.pharnext.com |
1177.HK | SINO BIOPHARM | Wan Chai | Hong Kong | HKD | HKG | 0.48 | 17.58 | 25579 | https://www.sinobiopharm.com |
0775.HK | CKLIFE SCIENCES | Tai Po | Hong Kong | HKD | HKG | 0.40 | 32.46 | 1855 | https://www.ck-lifesciences.com |
DNA | Ginkgo Bioworks Holdings, Inc. | Boston | United States | USD | NYQ | -1.24 | 641 | https://www.ginkgobioworks.com | |
002252.SZ | S/H RAAS BLOOD PRO | Shanghai | China | CNY | SHZ | 0.21 | 19.62 | 2966 | https://www.raas-corp.com |
002007.SZ | HUALAN BIOLOGICAL | Xinxiang | China | CNY | SHZ | 0.03 | 19.25 | 2927 | https://www.hualanbio.com |
600200.SS | JIANGSU WUZHONG PHARMACEUTICAL | Suzhou | China | CNY | SHH | 0.56 | -710.43 | https://www.600200.com | |
600866.SS | STAR LAKE BIOSCIENCE CO INC Z | Zhaoqing | China | CNY | SHH | 0.35 | 21.35 | 2608 | https://www.starlake.com.cn |
TRX.L | TISSUE REGENIX GROUP PLC | Garforth | United Kingdom | GBp | LSE | 1.40 | -10.94 | 79 | https://www.tissueregenix.com |
2269.HK | WUXI BIO | Wuxi | China | HKD | HKG | 0.91 | 85.17 | 9864 | https://www.wuxibiologics.com |
IMU.AX | IMUGENE FPO | Sydney | Australia | AUD | ASX | 2.28 | -30.30 | https://www.imugene.com | |
600201.SS | JINYU BIO-TECHNOLOGY CO LTD | Hohhot | China | CNY | SHH | 0.31 | 18.76 | 1580 | https://www.jinyu.com.cn |
TMBR | Timber Pharmaceuticals, Inc. | Basking Ridge | United States | USD | ASE | 0.19 | 5 | https://www.timberpharma.com | |
300181.SZ | ZHEJIANG JOLLY PHA | Huzhou | China | CNY | SHZ | 0.10 | 18.50 | 2132 | https://www.zuoli.com |
CLVS | Clovis Oncology, Inc. | Boulder | United States | USD | NMS | 0.49 | -3.78 | 413 | https://www.clovisoncology.com |
ATHX | Athersys, Inc. | Cleveland | United States | USD | NCM | -1.30 | -0.60 | 104 | https://www.athersys.com |
VTGN | VistaGen Therapeutics, Inc. | South San Francisco | United States | USD | NCM | 1.06 | 0.75 | 36 | https://www.vistagen.com |
300009.SZ | ANHUI ANKE BIOTECH | Hefei | China | CNY | SHZ | 0.38 | 19.32 | https://www.ankebio.com | |
300122.SZ | CHONGQING ZHIFEI B | Chongqing | China | CNY | SHZ | 0.77 | 11.89 | 4800 | https://www.zhifeishengwu.com |
2370.T | MEDINET CO LTD | Tokyo | Japan | JPY | JPX | 1.34 | -2.69 | 92 | https://www.medinet-inc.co.jp |
2137.HK | BRII-B | Beijing | China | HKD | HKG | -5.41 | 113 | https://www.briibio.com | |
1530.HK | 3SBIO | Shenyang | China | HKD | HKG | 0.84 | 6.75 | 5292 | https://www.3sbio.com |
1801.HK | INNOVENT BIO | Suzhou | China | HKD | HKG | -0.31 | -14.04 | 5568 | https://www.innoventbio.com |
300497.SZ | JIANGXI FUSHINE PH | Jingdezhen | China | CNY | SHZ | 0.14 | 35.19 | 1849 | https://www.fushine.cn |
300147.SZ | XIANGXUE PHARMACEU | Guangzhou | China | CNY | SHZ | 0.59 | 374.63 | 3378 | https://www.xphcn.com |
BLUE | bluebird bio, Inc. | Cambridge | United States | USD | NMS | 1.38 | -0.35 | 518 | https://www.bluebirdbio.com |
300204.SZ | STAIDSON (BEIJING) | Beijing | China | CNY | SHZ | 0.16 | -27.06 | 873 | https://www.staidson.com |
AKBA | Akebia Therapeutics, Inc. | Cambridge | United States | USD | NGM | 1.47 | -0.16 | 426 | https://www.akebia.com |
1873.HK | VIVA BIOTECH | Shanghai | China | HKD | HKG | 0.95 | 15.94 | 2127 | https://www.vivabiotech.com.cn |
300363.SZ | PORTON PHARMA SOLU | Chongqing | China | CNY | SHZ | -0.36 | 30.90 | 4158 | https://www.porton.cn |
VLON | Vallon Pharmaceuticals Inc. | Philadelphia | United States | USD | NCM | -1.15 | -0.24 | 2 | https://www.vallon-pharma.com |
SRNE | Sorrento Therapeutics, Inc. | San Diego | United States | USD | NCM | 2.17 | -2.59 | 799 | https://www.sorrentotherapeutics.com |
NVAX | Novavax, Inc. | Gaithersburg | United States | USD | NMS | 1.58 | -2.58 | 1541 | https://www.novavax.com |
300759.SZ | PHARMARON BEIJING | Beijing | China | CNY | SHZ | 0.28 | 49.23 | 14923 | https://www.pharmaron.com |
300404.SZ | BOJI MEDICAL & TEC | Guangzhou | China | CNY | SHZ | -0.10 | 63.41 | 989 | https://www.bojicro.com |
RIGL | Rigel Pharmaceuticals, Inc. | South San Francisco | United States | USD | NMS | 1.66 | -2.33 | 165 | https://www.rigel.com |
688180.SS | SHANGHAI JUNSHI BIOSCIENCES CO | Shanghai | China | CNY | SHH | 0.24 | -39.92 | 2805 | https://www.junshipharma.com |
600161.SS | BEIJING TIANTAN BIOLOGICAL PROD | Beijing | China | CNY | SHH | 0.02 | 23.29 | 3933 | https://www.tiantanbio.com |
9939.HK | KINTOR PHARMA-B | Suzhou | China | HKD | HKG | -0.77 | -5.99 | 316 | https://www.kintor.com.cn |
VERU | Veru Inc. | Miami | United States | USD | NCM | -0.41 | -41.18 | 252 | https://www.verupharma.com |
Funds
Mutual Fund Holders
Social
Dividends
Ratings
News
Earnings
SEC Filings
Options
Indicators
Glossary
- Momentum
- A technical indicator that measures the rate of change in price movements over a specific period. It indicates the strength or weakness of a price trend.
Assessment: A positive momentum value generally indicates a good trend, while a negative value suggests a weak or downward trend.
- Inertia
- In trading, inertia refers to the tendency of prices to continue moving in their current direction. It suggests that an asset's price will likely maintain its current trend.
Assessment: A higher inertia value is generally considered good, as it indicates a strong and sustained price trend.
- Relative Strength Index (RSI)
- A momentum oscillator that measures the speed and change of price movements. It helps identify overbought or oversold conditions in an asset.
Assessment: An RSI value above 70 is typically considered overbought and may suggest a potential reversal or correction. Conversely, an RSI value below 30 is often considered oversold, indicating a possible upward price correction.
- Fibonacci's Weighted Moving Average
- A technical indicator that assigns different weights to recent data points, giving more significance to recent prices. It helps smooth out price fluctuations and identify trend reversals.
Assessment: The interpretation of the Fibonacci's Weighted Moving Average value depends on its comparison to other moving averages or trendlines. A value above 50 may indicate an uptrend, while a value below 50 may suggest a downtrend.
- Williams %R
- A momentum indicator that measures overbought or oversold conditions in an asset. It shows the relationship of the current closing price to the high-low range over a specified period.
Assessment: Williams %R values above -20 are typically considered overbought and may indicate a potential price reversal. Values below -80 are often viewed as oversold, suggesting a potential price bounce.
- Relative Volatility Index (RVI)
- A technical indicator that measures the volatility of a security by comparing the magnitude of recent price movements to the magnitude of average price changes. It helps identify periods of high or low volatility.
Assessment: A higher RVI value suggests higher volatility, which can provide trading opportunities but also carries increased risk.
- Commodity Channel Index (CCI)
- A versatile indicator that measures the current price level relative to an average price level over a given period. It helps identify overbought or oversold conditions and potential trend reversals.
Assessment: CCI values above 100 are often considered overbought, indicating a potential price correction or reversal. Values below -100 are typically viewed as oversold, suggesting a potential price rebound.